HOME

RINVOQ AD

HUMIRA

SKYRIZI

SKINVERSATIONS

SERVICES

CONTACT

SERVICES

SERVICES

At AbbVie, patient care doesn’t stop at the prescription

AbbVie has a legacy of partnership in dermatology to advance the standard of care. We aspire to tackle global challenges in dermatology and shape the future of disease management.

Compassionate Access Program

Request compassionate supply of AbbVie medicines

Patient Support

Services and tools to support your HUMIRA & Skyrizi patients patients

RINVOQ.com.au

Support, services and tools for your Rinvoq patients on their treatment journey​

Destination Pharmacy
Destination Pharmacy

Selected pharmacies with services to better assist your patients

ACCESS NOW ➜

Skinversations

Find the latest news on all things dermatology

Submit a report or request

Please select the action you wish to take.

Request a product sample

Report a product quality complaint

Report an adverse event

More for you


SKYRIZI    

Learn more

RINVOQ AD

Learn more

About HUMIRA

Learn more

Your decisions have transformed the
lives of many patients

AbbVie and HUMIRA - your partners on the journey.*

*AbbVie medications and programs are designed to support patients on their health journey.

Your decisions have transformed the lives of many patients

AbbVie and HUMIRA - your partners on the journey.*

*AbbVie medications and programs are designed to support patients on their health journey.


PBS Information

RINVOQ: Authority required. Refer to PBS Schedule for full authority information.

HUMIRA: Authority required. Refer to PBS Schedule for full authority information. This product is not listed on the PBS for the treatment of enthesitis-related arthritis or paediatric psoriasis.

SKYRIZI: Authority required for the treatment of adults with severe plaque psoriasis. SKYRIZI is not listed on the PBS for the treatment of psoriatic arthritis. Refer to PBS Schedule for full authority information.

Please review the full Product Information (PI) before prescribing, available below.

AU-DERM-220001. August 2024